On June 2, 2014 Karyopharm Therapeutics Inc. (NASDAQ:KPTI) a clinical-stage pharmaceutical company, announced multiple presentations of clinical data from an ongoing Phase 1 trial of its lead drug candidate, Selinexor (KPT-330), in patients with advanced or metastatic solid tumors and an ongoing Phase 1b food effects study of Selinexor in patients with advanced sarcomas at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Karyopharm Therapeutics Inc (NASDAQ:KPTI) weekly performance is -4.11%. On last trading day company shares ended up $25.17. Analysts mean target price for the company is $48.25. Karyopharm Therapeutics Inc (NASDAQ:KPTI) distance from 50-day simple moving average (SMA50) is -12.15%.
On June 5, Titan Machinery Inc (NASDAQ:TITN) a leading network of full-service agricultural and construction equipment stores, reported financial results for the fiscal first quarter ended April 30, 2014. For the first quarter of fiscal 2015, revenue was $465.5 million, compared to $441.7 million in the first quarter last year. Equipment sales were $345.0 million for the first quarter of fiscal 2015, compared to $334.7 million in the first quarter last year. Parts sales were $68.4 million for the first quarter of fiscal 2015, compared to $62.8 million in the first quarter last year. Titan Machinery Inc. (NASDAQ:TITN) shares fell -5.19% in last trading session and ended the day on $16.98. Gross Margin is 15.60% and its return on assets is 0.70%. Titan Machinery Inc. (NASDAQ:TITN) quarterly performance is 3.98%.
On June 6, Hyperion Therapeutics, Inc. (NASDAQ:HPTX) has been informed that Sofinnova Venture Partners VII, L.P. executed a block trade for 417,747 shares of the Company’s common stock on or about June 4, 2014. Dr. James Healy, a member of the Company’s Board of Director’s, is a managing member of Sofinnova Management VII, L.L.C., the general partner of Sofinnova Venture Partners VII, L.P., and may be considered to have beneficial ownership of Sofinnova Venture Partners VII, L.P.’s interest in us. Dr. Healy disclaims beneficial ownership in our shares owned by Sofinnova Venture Partners VII, L.P. Hyperion Therapeutics Inc (NASDAQ:HPTX) shares moved down -9.41% in last trading session and was closed at $26.95, while trading in range of $26.31 – $29.25. Hyperion Therapeutics Inc (NASDAQ:HPTX) year to date (YTD) performance is 33.28 %.
On June 6, First NBC Bank Holding Company (NASDAQ:NBCB) was downgraded by Sterne Agee from a “buy” rating to a “neutral” rating in a research note issued on Friday. First NBC Bank Holding Company (NASDAQ:NBCB) ended the last trading day at $32.04. Company weekly volatility is calculated as 4.04% and price to cash ratio as 1.65. First NBC Bank Holding Company (NASDAQ:NBCB) showed a negative weekly performance of -5.49%.
June 3, 2014 AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced the results of a cost analysis study that showed the use of intravenous patient-controlled analgesia, IV PCA, can typically cost a health system more than $200 in opioid drug and IV PCA equipment costs per patient over a typical 2-day postoperative in-hospital stay. AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) net profit margin is -70.40% and weekly performance is -9.78%. On last trading day company shares ended up $8.30. Analysts mean target price for the company is $15.69. AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) distance from 50-day simple moving average (SMA50) is -18.83%.